Table 1.
Clinical information of included patients.
| Factors | TKIs group, n=39 (%) | TKIs + ICIs group, n=19 (%) | P value |
|---|---|---|---|
| age | |||
| <50 | 16 (41.0) | 5 (26.3) | |
| 50-59 | 19 (48.7) | 4 (21.1) | |
| ≥60 | 4 (10.3) | 10 (52.6) | 0.002 |
| gender | |||
| female | 4 (10.3) | 7 (36.8) | |
| male | 35 (89.7) | 12 (63.2) | 0.029 |
| HB | |||
| ≥110g/L | 30 (76.9) | 13 (68.4) | |
| <110g/L | 9 (23.1) | 6 (31.6) | 0.488 |
| PLT | |||
| ≥100×109/L | 22 (56.3) | 14 (73.7) | |
| <100×109/L | 17 (43.6) | 5 (26.3) | 0.203 |
| Child-Pugh | |||
| A | 29 (74.4) | 11 (57.9) | |
| B | 7 (17.9) | 7 (36.8) | |
| C | 3 (7.7) | 1 (5.3) | 0.286 |
| Tumor stage | |||
| BCLC A | 3 (7.7) | 4 (21.1) | |
| BCLC B | 33 (56.4) | 10 (52.6) | |
| BCLC C | 14 (35.9) | 5 (26.3) | 0.320 |
| HBV | |||
| negative | 4 (10.3) | 2 (10.5) | |
| positive | 35 (89.7) | 17 (89.5) | 0.975 |
| TKIs | |||
| Sorafenib | 32 (82.1) | 14 (73.7) | |
| Lenvatinib | 7 (17.9) | 5 (26.3) | 0.460 |
TKIs, Tyrosine kinase inhibitor; ICIs, Immune checkpoint inhibitor; HB, hemoglobin; PLT, platelet; BCLC, Barcelona Clinic Liver Cancer; HBV, Hepatitis B Virus.